An appropriate DNA input for bisulfite conversion reveals LINE-1 and Alu hypermethylation in tissues and circulating cell-free DNA from cancers.

Journal: PloS one
PMID:

Abstract

The autonomous and active Long-Interspersed Element-1 (LINE-1, L1) and the non-autonomous Alu retrotransposon elements, contributing to 30% of the human genome, are the most abundant repeated sequences. With more than 90% of their sequences being methylated in normal cells, these elements undeniably contribute to the global DNA methylation level and constitute a major part of circulating-cell-free DNA (cfDNA). So far, the hypomethylation status of LINE-1 and Alu in cellular and extracellular DNA has long been considered a prevailing hallmark of ageing-related diseases and cancer. This study demonstrated that errors in LINE-1 and Alu methylation level measurements were caused by an excessive input quantity of genomic DNA used for bisulfite conversion. Using the minuscule DNA amount of 0.5 ng, much less than what has been used and recommended so far (500 ng-2 μg) or 1 μL of cfDNA extracted from 1 mL of blood, we revealed hypermethylation of LINE-1 and Alu in 407 tumour samples of primary breast, colon and lung cancers when compared with the corresponding pair-matched adjacent normal tissue samples (P < 0.05-0.001), and in cfDNA from 296 samples of lung cancers as compared with 477 samples from healthy controls (P < 0.0001). More importantly, LINE-1 hypermethylation in cfDNA is associated with healthy ageing. Our results have not only contributed to the standardized bisulfite-based protocols for DNA methylation assays, particularly in applications on repeated sequences but also provided another perspective for other repetitive sequences whose epigenetic properties may have crucial impacts on genome architecture and human health.

Authors

  • Trang Thi Quynh Tran
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.
  • Tung The Pham
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.
  • Than Thi Nguyen
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.
  • Trang Hien Do
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.
  • Phuong Thi Thu Luu
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.
  • Uyen Quynh Nguyen
    VNU Institute of Microbiology and Biotechnology, Hanoi, Vietnam.
  • Linh Dieu Vuong
    Pathology and Molecular Biology Center, Vietnam National Cancer Hospital, Hanoi, Vietnam.
  • Quang Ngoc Nguyen
    Pathology and Molecular Biology Center, Vietnam National Cancer Hospital, Hanoi, Vietnam.
  • Son Van Ho
    Department of Chemistry, 175 Hospital, Ho Chi Minh City, Vietnam.
  • Hang Viet Dao
    Endoscopic Centre, Hanoi Medical University Hospital, Hanoi, Vietnam.
  • Tong Van Hoang
    Institute of Biomedicine and Pharmacy, Ha Dong, Vietnam.
  • Lan Thi Thuong Vo
    Faculty of Biology, VNU University of Science, Vietnam National University, Hanoi, Vietnam.